News Article | February 24, 2017
The International Nurses Association is pleased to welcome Darria M. Lloyd, RN, BSN, to their prestigious organization with her upcoming publication in the Worldwide Leaders in Healthcare. Darria M. Lloyd is a Registered Nurse with 16 years of experience in her field and an extensive expertise in all facets of nursing, especially oncology and critical care nursing. Darria is currently serving patients within Newark Beth Israel Medical Center, Bayonne Medical Center in Bayonne, New Jersey and is also affiliated with Hackensack University Medical Center. Darria M. Lloyd attended Essex County College in Newark, New Jersey, graduating with her Associate’s Degree in Nursing in 2000. An advocate for continuing education, she went on to gain her Bachelor of Science Degree in Nursing from New Jersey City University, followed by her Master of Science Degree in Nursing as Adult- Gerontology Primary Care Nurse Practitioner in 2016 from Saint Peter’s University in Jersey City. She holds additional certification as an Advanced Oncology Certified Nurse, Progressive Care Certified Nurse and now APRN A-GNP-C. She attributes her success to her determination, her desire to become a nurse, and overcoming challenges. In her free time, Darria enjoys running Spartan races. Learn more about Darria M. Lloyd here: http://inanurse.org/network/index.php?do=/4133071/info/ and be sure to read her upcoming publication in Worldwide Leaders in Healthcare.
News Article | March 1, 2017
TAMPA, Fla.--(BUSINESS WIRE)--A team of former health system CEOs and other senior executives has joined forces to launch CSuite Solutions, a strategic advisory firm serving health system leaders across the U.S. The new consultancy will harness decades of combined experience to help health systems thrive in today’s challenging environment while also preparing for the transition from volume-based business models to value-based care. “We know the challenges that healthcare leaders are facing because we’ve sat in those chairs ourselves,” said Steve Mason, co-founder of CSuite Solutions and former CEO of BayCare Health System in the Tampa Bay and Central Florida regions. “Having an intimate understanding of the decisions our clients face equips us to provide strategic, real-world counsel.” Although the transition to value-based care is a priority for the healthcare industry, leadership at CSuite Solutions recognizes that there is still a need to help health systems operate successfully within the traditional volume-based business model. “Volume is not dead,” said Stewart Schaffer, co-founder of CSuite Solutions and former chief marketing and strategy officer at BayCare. “There are hospitals and practices struggling with issues including reduced reimbursement rates, revenue cycle challenges and declining market share. We can help them manage these challenges today while also laying a foundation for the changes that are still to come.” Including Mason and Schaffer, CSuite is launching operations with a total of seven partners. The other partners are: Josh Adler, former president of Archimedes Clinical Analytics, formerly a subsidiary of Kaiser Permanente; Jim Burkhart, former CEO of Tampa General Hospital; Stephen Jacobs, MD, FACP, a board certified internal medicine specialist and former president of Morton Plant Mease Primary Care, Inc.; Brian Paradis, former president and chief operating officer of Florida Hospital’s Central Region; and Jeffrey Rivest, former president and CEO of the University of Maryland Medical Center. In addition to revenue cycle optimization and value-based care delivery, CSuite Solutions offers expertise in a wide array of issues facing health system leaders including Accountable Care Organizations, physician alignment, managed care contracting, patient acquisition, population health, clinically integrated network development and health information technology. CSuite Solutions is a national strategic advisory firm serving health systems across the U.S. The practice is led by accomplished healthcare industry executives who have transformed hospitals and major healthcare systems, physician groups and other providers into financially robust organizations. These C-level executives are now dedicating their talents and connections to helping their peers successfully navigate these transformative times. To learn more about CSuite Solutions and its service offerings, please visit CSuiteSolutions.com and follow @CSuiteSolutions on Twitter.
News Article | February 28, 2017
The American Student Dental Association honors Dr. Linda Niessen, dean and professor at Nova Southeastern University College of Dental Medicine, with its highest honor, the Paragon Award. Chicago, IL, February 28, 2017 --( The Paragon Award recognizes an individual who has significantly contributed to the advancement of the rights, interests and welfare of dental students throughout his or her career. It is the highest and most notable award given by ASDA. “In three short years, Dr. Niessen has transformed the dental student experience at Nova Southeastern University College of Dental Medicine. Students are actively engaged in organized dentistry and committed to service and academic excellence. She inspires them to think critically about dentistry and seek opportunities for improvement and growth,” says Adam Saltz, Nova Southeastern ’17, ASDA editor in chief. “As a world-renowned lecturer on public health issues, Dr. Niessen gives voice to the inequalities that exist in the oral healthcare system for women and the elderly. I proudly consider her my dean, mentor and friend.” Dr. Niessen has been active in dental organizations throughout her career. In the past, she served as president of the American Academy of Esthetic Dentistry (AAED), president of the American Association for Women Dentists (AAWD), president of the American Association of Public Health Dentistry (AAPHD) and president of the Dallas County Dental Society. Among her professional achievements, Dr. Niessen is also a member on the U.S. Department of Health and Human Services Advisory Committee on Training in Primary Care Medicine and Dentistry. She joined the Nova Southeastern University faculty as dean and professor of the College of Dental Medicine in October 2013. Dr. Niessen is a graduate of the Harvard School of Dental Medicine (DMD), and received her public health degree (MPH) at the Harvard School of Public Health. In addition, she earned a master's degree in public policy (MPP) from the Kennedy School of Government at Harvard. “It is an honor to receive the Paragon Award from the American Student Dental Association. This award is a tribute to all the faculty and mentors in my life who helped prepare me for a career in dental education,” Dr. Niessen remarked in her acceptance speech. “I thank the incredibly talented students, outstanding faculty and dedicated staff at Nova Southeastern University College of Dental Medicine for their support and my family for their encouragement throughout my dental career. I dedicate this award to all ASDA students with a hope that as you realize your potential as dentists, you pay it forward and consider dental education as part of your career plans.” Dr. Niessen is the fifth recipient of ASDA’s Paragon Award, and the first female honoree. Past recipients include Dr. Arthur A. Dugoni (2011), Dr. Roger Triftshauser (2012), Dr. William Calnon (2015) and Dr. Gregory Chadwick (2016). More information on the Paragon Award is available at ASDAnet.org/paragon. About ASDA The American Student Dental Association is the largest national organization that protects and advances the rights, interests and welfare of dental students and predentals. Representing 90 percent of all dental students, ASDA introduces students to lifelong involvement in organized dentistry and provides services, information, education, representation and advocacy. For more information, visit ASDAnet.org. Chicago, IL, February 28, 2017 --( PR.com )-- The American Student Dental Association (ASDA) is pleased to announce Dr. Linda C. Niessen, dean and professor of Nova Southeastern University College of Dental Medicine, as the recipient of this year’s Paragon Award. Dr. Niessen was presented the prestigious award during ASDA’s Annual Session in Orlando on Feb. 25, 2017.The Paragon Award recognizes an individual who has significantly contributed to the advancement of the rights, interests and welfare of dental students throughout his or her career. It is the highest and most notable award given by ASDA.“In three short years, Dr. Niessen has transformed the dental student experience at Nova Southeastern University College of Dental Medicine. Students are actively engaged in organized dentistry and committed to service and academic excellence. She inspires them to think critically about dentistry and seek opportunities for improvement and growth,” says Adam Saltz, Nova Southeastern ’17, ASDA editor in chief. “As a world-renowned lecturer on public health issues, Dr. Niessen gives voice to the inequalities that exist in the oral healthcare system for women and the elderly. I proudly consider her my dean, mentor and friend.”Dr. Niessen has been active in dental organizations throughout her career. In the past, she served as president of the American Academy of Esthetic Dentistry (AAED), president of the American Association for Women Dentists (AAWD), president of the American Association of Public Health Dentistry (AAPHD) and president of the Dallas County Dental Society. Among her professional achievements, Dr. Niessen is also a member on the U.S. Department of Health and Human Services Advisory Committee on Training in Primary Care Medicine and Dentistry. She joined the Nova Southeastern University faculty as dean and professor of the College of Dental Medicine in October 2013.Dr. Niessen is a graduate of the Harvard School of Dental Medicine (DMD), and received her public health degree (MPH) at the Harvard School of Public Health. In addition, she earned a master's degree in public policy (MPP) from the Kennedy School of Government at Harvard.“It is an honor to receive the Paragon Award from the American Student Dental Association. This award is a tribute to all the faculty and mentors in my life who helped prepare me for a career in dental education,” Dr. Niessen remarked in her acceptance speech. “I thank the incredibly talented students, outstanding faculty and dedicated staff at Nova Southeastern University College of Dental Medicine for their support and my family for their encouragement throughout my dental career. I dedicate this award to all ASDA students with a hope that as you realize your potential as dentists, you pay it forward and consider dental education as part of your career plans.”Dr. Niessen is the fifth recipient of ASDA’s Paragon Award, and the first female honoree. Past recipients include Dr. Arthur A. Dugoni (2011), Dr. Roger Triftshauser (2012), Dr. William Calnon (2015) and Dr. Gregory Chadwick (2016). More information on the Paragon Award is available at ASDAnet.org/paragon.About ASDAThe American Student Dental Association is the largest national organization that protects and advances the rights, interests and welfare of dental students and predentals. Representing 90 percent of all dental students, ASDA introduces students to lifelong involvement in organized dentistry and provides services, information, education, representation and advocacy. For more information, visit ASDAnet.org. Click here to view the list of recent Press Releases from American Student Dental Association
News Article | February 15, 2017
Vanguard Medical Group is one of nearly 2,900 primary care practices nationwide participating in Comprehensive Primary Care Plus (CPC+), a partnership that aims to enable primary care practices to care for their patients the way they think will deliver the best outcomes and to pay them for achieving results and improving care. This partnership involves payer partners from the Centers for Medicare & Medicaid Services (CMS), state Medicaid agencies, commercial health plans, self-insured businesses, and primary care providers. For patients, this means that Vanguard physicians may offer longer and more flexible hours; use electronic health records; coordinate care with patients' other health care providers; better engage patients and caregivers in managing their own care; and provide individualized, enhanced care for patients living with multiple chronic diseases and higher needs. "CPC plus is a great opportunity for primary care practices such as Vanguard to improve and transform themselves to better meet the needs of our patients. Without this program, this improvement would be extremely difficult if not impossible for practices to do on their own" said Vanguard Chief Medical Officer Thomas McCarrick MD, MBI. Through a competitive application process, CMS selected primary care practices such as Vanguard Medical Group within selected markets to participate in CPC+. Vanguard was chosen based on its use of health information technology; recognition of advanced primary care delivery by the National Committee for Quality Assurance (NCQA); service to patients covered by participating payer partners; participation in practice transformation and improvement activities; and diversity of geography, practice size, and ownership structure. CPC+ is administered by the Center for Medicare & Medicaid Innovation (CMS Innovation Center). The CMS Innovation Center was created by the Affordable Care Act to test innovative payment and service delivery models that have the potential to reduce program expenditures while preserving or enhancing the quality of care. For more information about CPC+, visit: https://innovation.cms.gov/initiatives/comprehensive-primary-care-plus/ About Vanguard Medical Group Vanguard Medical Group P.C. is a regional primary care practice now serving more than 48,000 active patients in six locations. The motivation to develop a larger, regional primary care practice was the recognition that the healthcare system was rapidly changing in ways that did not support small or solo independent physician practices. The founding physicians in Vanguard believe that a strong culture of locally-led practices, guided by a shared vision, and governed by shared values must be at the core of this new organization. For more information on Vanguard Medical Group please visit http://www.vanguardmedgroup.com
News Article | February 20, 2017
ORLANDO, Fla.--(BUSINESS WIRE)--HIMSS Conference, Booth #150—eClinicalWorks®, a leader in ambulatory healthcare IT solutions, furthers its contribution to advancing affordable nationwide health data sharing by announcing its successful deployment of CommonWell Health Alliance services. As a Contributor Member of CommonWell, eClinicalWorks can now support the seamless exchange of data for its customers. Built on a vendor-neutral platform, CommonWell services are built directly in a member company’s software, allowing health information to easily be shared among participating care locations and across disparate EHRs. To date, CommonWell has more than 9,800 provider sites committed to using its interoperability services, including more than 5,100 live today. All practices that have upgraded to the latest version of the eClinicalWorks software are eligible to activate CommonWell services. CommonWell integration for patient linking and enrollment is tightly integrated into the eClinicalWorks Practice Management workflows and once network links are established per patient, eClinicalWorks has automated the clinical data retrieval from external systems to be fetched and rendered in the right chart panel of the progress note. The CommonWell services also allow users in other systems to query and retrieve the CCDAs of common patients from eClinicalWorks practices for the purposes of treatment. Primary Care of the Andovers, a Circle Health affiliated primary care practice using eClinicalWorks EHR for past 3 years said, “CommonWell Health Alliance was critical in enabling the interoperability that was needed between our practice, which is on eClinicalWorks, and Lowell General Hospital, which uses Cerner. This connection truly helps us better coordinate care. We have a significant patient population overlap with the hospital and being able to seamlessly exchange information within the EHR workflow creates a big win for the clinicians at our practice, the hospital providers and the patients who ultimately get the best possible care." “CommonWell Health Alliance is focused on reaching the full continuum of care and helping to ensure pertinent patient information is available to caregivers and individuals regardless of where care occurred,” said Jitin Asnaani, Executive Director of CommonWell Health Alliance. “We are excited to have eClinicalWorks offering CommonWell services to its customers. As one of the largest cloud-based EHR vendors, it further expands our reach in the important ambulatory market.” “eClinicalWorks has developed strong partnerships and continued collaborations with its customers and industry vendors with the main goal of making it easier for providers to share data across systems,” said Girish Navani, CEO and co-founder of eClinicalWorks. “As a member of CommonWell Health Alliance, eClinicalWorks is committed to providing affordable interoperability to all customers to facilitate coordination of care and to ensure providers have complete and accurate patient information.” About CommonWell Health Alliance CommonWell Health Alliance is a not-for-profit trade association of health IT companies working together to create universal access to health data nationwide. CommonWell members represent two-thirds of the acute care EHR market and more than one-third of the ambulatory care EHR market, as well as market leaders and technology innovators supporting care settings such as post-acute care, imaging, perinatal, laboratory, retail pharmacy, oncology, population health, emergency services and more. CommonWell and its members are committed to the belief that provider access to health data must be built into information technologies at a reasonable cost for use by a broad range of health care providers and the populations and people they serve. To learn more about CommonWell Health Alliance, visit www.commonwellalliance.org. Engage with CommonWell on our Blog, as well as through Facebook, LinkedIn and Twitter using the handle, @CommonWell. CommonWell Health Alliance® and the CommonWell Logo are registered trademarks of CommonWell Health Alliance Inc. About eClinicalWorks eClinicalWorks® is a privately held leader in healthcare IT solutions. With more than 125,000 physicians and nurse practitioners using its solutions, customers include ACOs, physician practices, hospitals, community health centers, departments of health, and convenient care clinics. During the past eight years, 16 eClinicalWorks customers have received the prestigious HIMSS Davies Award, honoring excellence in electronic health record implementation. The company is second largest in the country for e-prescribing. Based in Westborough, Mass., eClinicalWorks has additional offices in Austin, New York City, Chicago, California, Georgia, London, India, and Dubai. For more information, please visit www.eclinicalworks.com, Facebook, Twitter or call 866-888-6929. eClinicalWorks is a trademark of eClinicalWorks, LLC. All other trademarks or service marks contained herein are the property of their respective owners.
News Article | February 21, 2017
MOUNTAIN VIEW, Calif.--(BUSINESS WIRE)--Student athletes from the University of Wyoming (UW) are being asked to volunteer in a clinical study to further development of the BrainPulseTM device by Jan Medical. UW is a Division I athletics university with over 400 student athletes. The study began in early December 2016 and over 200 male and female student athletes have enrolled so far. The research team at Jan Medical is working with the school’s sports medicine and athletic departments to collect concussion data. Participation in this study is completely voluntary and is being conducted under a well-defined clinical protocol. “Concussion research has exploded nationally over the last few years. Although student athletes are not required to enroll in the study, the high rate of participation so far signifies the importance of concussion research among our athletes,” said Matthew Boyer, DO, Medical Director and Head Team Physician for Primary Care and Sports Medicine at University of Wyoming. “We appreciate all of our athletes whom have donated their time for this project.” The study device, BrainPulse by Jan Medical, utilizes a novel, non-invasive approach to obtain neurophysiological parameters that can provide clinically useful information for diagnosis of brain pathologies such as stroke and traumatic brain injuries. The BrainPulse system operates using a passive headset and small computer. The headset, similar to a bike helmet, sits on top of the head and uses highly responsive sensors to detect movement of the skull via vibrations on the surface of the skin. These vibrations, produced by heartbeat and blood flow into the brain, are naturally occurring in every person. Each sensor includes a small crystal that reacts to motion, which is then recorded by the computer. Since the headset is a monitoring device only, no energy such as electricity, radiation or heat, is being generated or transmitted to the participant’s head. The BrainPulse technology is the first of its kind and has received de novo clearance by the FDA as a cranial motion measurement device. Both concussed and non-concussed student athletes will participate in the recording phase of the clinical trial to produce an accurate side-by-side analysis. Participation will involve at least one recording with the BrainPulse device, and some athletes will complete multiple recording sessions depending on their exposure to injury. Each recording session lasts approximately three minutes and requires the participant to sit still during that time period. All information collected in the voluntary study will be considered confidential. The evaluation of symptoms, physical examination, neurological baseline testing and device recordings will be entered in a database to determine clinical outcomes and assess the BrainPulse device efficacy. “Correlating this device to concussions objectively will be groundbreaking for future implications including rehabilitation care, classroom activity and return to sports activity,” stated Ryan Pinson, M.Ed. ATC / LAT, Director of Sports Medicine at University of Wyoming. “Our number one goal is optimal healthcare for the student athletes, and I feel we are making breakthroughs with innovation and research.” “We are excited to work with Jan Medical in their effort to progress diagnosis and management of athletically related concussions with the BrainPulse device,” commented Cole Vertz, MS ATC / LAT, Associate Athletic Trainer and Director of Rehabilitation at University of Wyoming. The specific purpose of this study at UW is to collect data to improve BrainPulse algorithms that aid in the diagnosis of concussion. All information collected may aid doctors in understanding specific conditions of the brain that result from concussion or other traumatic brain injuries, establishing the areas of greatest benefit for this emerging technology. To learn more about the BrainPulse device, visit http://www.janmedical.com/education/concussion/. University of Wyoming Athletics competes at the highest level of collegiate sports – the NCAA Division I level. UW is a founding member of the Mountain West Conference and offers 17 NCAA Division I sports, including nine women’s sports and eight men’s sports. Of Wyoming’s 17 sports, 15 compete as members of the Mountain West. The Wyoming wrestling program competes as a member of the Big 12 Conference and the men’s swimming and diving program competes as a member of the Western Athletic Conference. Over 400 student-athletes represent Cowboy and Cowgirl Athletics. The University of Wyoming is the only four-year institution of higher education in the state of Wyoming, making the entire state of Wyoming Cowboy and Cowgirl fans. Jan Medical is a medical device start-up dedicated to providing physicians critical data for accelerating and expanding therapy while improving the diagnostic experience for patients with brain disorders. Its proprietary platform technology, BrainPulse, uses accelerometers on a non-invasive headset to detect skull motion resulting from pulsatile blood flow into the brain. The BrainPulse is currently involved in research projects to study the brain pulse patterns and develop algorithms for concussion, vasospasm and other indications. CAUTION: The Jan Medical BrainPulse system is a FDA cleared device that is investigational for concussion evaluation limited by federal (US) law to investigational use.
News Article | February 15, 2017
PAINWeekEnd (PWE) Anaheim, on February 18 and 19 at the Hyatt Regency Orange County, 11999 Harbor Blvd, will be an educational and exciting 2-day program providing busy clinicians and allied healthcare practitioners with 12.0 hours of relevant, practical instruction in the management of chronic pain. California has a 1-time requirement of 12 CME credits in pain management and treatment of terminally ill and dying patients, which must be finished before the second license renewal date or within 4 years, whichever occurs first. By attending PAINWeekEnd Anaheim, participants can enhance their skills in medication risk evaluation and mitigation, pain assessment and diagnosis, and delivery of individualized multimodal treatment. Course topics/titles (subject to change) include Chronic Pain Assessment; How Does Acute Pain Become Chronic?; Minimizing Pills and Maximizing Skills: Achieving Successful Opioid Cessation in Chronic Pain; Functional Pain Syndromes; Interdisciplinary Management of Pelvic Pain: Bridging the Gap Between Primary Care and Specialty Referral; Assessing and Managing Insomnia in Patients with Chronic Pain; If 6 Were 9: The CDC’s Prescribing Guidelines and the Veil of Secrecy; Nonopioid Analgesics: Antidepressants, Adjuvant Therapies, and Muscle Relaxants; Embrace 2017 Practice Changes and Patient Education: Mitigate Clinical and Legal Risks; The Medical Stasi: Is Risk Management for Controlled Substances Destroying the Provider-Patient Relationship?; Not for Human Consumption: New Drugs of Abuse and Their Detection; Get Your Specimens in Order: How to Avoid Bad Company and Tame the Paper Beast Associated With Testing Drugs of Abuse. In addition, there will be commercially supported activities addressing a range of product, disease state, and medical information topics. To see the complete agenda and more information about this or other PAINWeekEnd Regional Conferences, go to painweekend.org. The online registration fee for this PAINWeekEnd Conference is $199. PAINWeekEnd registrants are further offered the opportunity to register for the 2017 PAINWeek National Conference, September 5-9, in Las Vegas, for $129 off the current online published price.
News Article | March 2, 2017
Ipsen (Euronext: IPN; ADR: IPSEY) today announced the appointment of Benoit Hennion as Executive Vice President and President, Primary Care, effective 13 March 2017. Mr. Hennion will report directly to David Meek, CEO of Ipsen, and will join the Executive Leadership Team. Jean Fabre, who has led the Primary Care business since 2011 will step down from the position in March 2017 to pursue a new career opportunity at another company. David Meek, CEO of Ipsen, commented: “I would like to acknowledge the tremendous contribution made by Jean Fabre, who has been with our company for nearly a decade. It is my great pleasure to welcome his successor, Benoit Hennion, to the Executive Leadership Team as Executive Vice President and President, Primary Care. Throughout his 11 years at Ipsen, Benoit has consistantly demonstrated his strategic vision and ability to drive change. His thorough knowledge of Ipsen’s Primary Care portfolio, together with his broad, international leadership experience and indisputable leadership skills, will enable Benoit to play a central role in the on-going transformation of our global Primary Care operations into a sustainable business focused on meeting our patients’ needs.” Mr. Hennion joined Ipsen in 2006 within the Corporate Strategic Planning team. In 2009, he became Primary Care Business Unit Head for France, and subsequently, in 2011, General Manager of France Operations (including both Specialty Care and Primary Care). Following the split between Specialty Care and Primary Care in 2014, Mr. Hennion was appointed Vice President, Asia-Pacific Specialty Care. Mr. Hennion earned his MBA degree at ESSEC (Paris, France). Before joining Ipsen, he started his career at Societe Generale in the Czech Republic and then served for six years at the Paris office of Roland Berger Strategy Consultants. About Ipsen Ipsen is a global specialty-driven pharmaceutical group with total sales close to €1.6 billion in 2016. Ipsen sells more than 20 drugs in more than 115 countries, with a direct commercial presence in more than 30 countries. Ipsen’s ambition is to become a leader in specialty healthcare solutions for targeted debilitating diseases. Its fields of expertise cover oncology, neurosciences and endocrinology (adult & pediatric). Ipsen’s commitment to oncology is exemplified through its growing portfolio of key therapies improving the care of patients suffering from prostate cancer, neuro-endocrine tumors, renal cell carcinoma and pancreatic cancer. Ipsen also has a significant presence in primary care. Moreover, the Group has an active policy of partnerships. Ipsen's R&D is focused on its innovative and differentiated technological platforms, peptides and toxins, located in the heart of the leading biotechnological and life sciences hubs (Les Ulis/Paris-Saclay, France; Slough/Oxford, UK; Cambridge, US). In 2016, R&D expenditures exceeded €200 million. The Group has more than 4,900 employees worldwide. Ipsen’s shares are traded on segment A of Euronext Paris (stock code: IPN, ISIN code: FR0010259150) and are eligible to the “Service de Règlement Différé” (“SRD”). The Group is part of the SBF 120 index. Ipsen has implemented a Sponsored Level I American Depositary Receipt (ADR) program, which trades on the over-the-counter market in the United States under the symbol IPSEY. For more information on Ipsen, visit www.ipsen.com. Forward Looking Statement The forward-looking statements, objectives and targets contained herein are based on the Group’s management strategy, current views and assumptions. Such statements involve known and unknown risks and uncertainties that may cause actual results, performance or events to differ materially from those anticipated herein. All of the above risks could affect the Group’s future ability to achieve its financial targets, which were set assuming reasonable macroeconomic conditions based on the information available today. Use of the words "believes," "anticipates" and "expects" and similar expressions are intended to identify forward-looking statements, including the Group’s expectations regarding future events, including regulatory filings and determinations. Moreover, the targets described in this document were prepared without taking into account external growth assumptions and potential future acquisitions, which may alter these parameters. These objectives are based on data and assumptions regarded as reasonable by the Group. These targets depend on conditions or facts likely to happen in the future, and not exclusively on historical data. Actual results may depart significantly from these targets given the occurrence of certain risks and uncertainties, notably the fact that a promising product in early development phase or clinical trial may end up never being launched on the market or reaching its commercial targets, notably for regulatory or competition reasons. The Group must face or might face competition from generic products that might translate into a loss of market share. Furthermore, the Research and Development process involves several stages each of which involves the substantial risk that the Group may fail to achieve its objectives and be forced to abandon its efforts with regards to a product in which it has invested significant sums. Therefore, the Group cannot be certain that favorable results obtained during pre-clinical trials will be confirmed subsequently during clinical trials, or that the results of clinical trials will be sufficient to demonstrate the safe and effective nature of the product concerned. There can be no guarantees a product will receive the necessary regulatory approvals or that the product will prove to be commercially successful. If underlying assumptions prove inaccurate or risks or uncertainties materialize, actual results may differ materially from those set forth in the forward-looking statements. Other risks and uncertainties include but are not limited to, general industry conditions and competition; general economic factors, including interest rate and currency exchange rate fluctuations; the impact of pharmaceutical industry regulation and health care legislation; global trends toward health care cost containment; technological advances, new products and patents attained by competitors; challenges inherent in new product development, including obtaining regulatory approval; the Group's ability to accurately predict future market conditions; manufacturing difficulties or delays; financial instability of international economies and sovereign risk; dependence on the effectiveness of the Group’s patents and other protections for innovative products; and the exposure to litigation, including patent litigation, and/or regulatory actions. The Group also depends on third parties to develop and market some of its products which could potentially generate substantial royalties; these partners could behave in such ways which could cause damage to the Group’s activities and financial results. The Group cannot be certain that its partners will fulfil their obligations. It might be unable to obtain any benefit from those agreements. A default by any of the Group’s partners could generate lower revenues than expected. Such situations could have a negative impact on the Group’s business, financial position or performance. The Group expressly disclaims any obligation or undertaking to update or revise any forward looking statements, targets or estimates contained in this press release to reflect any change in events, conditions, assumptions or circumstances on which any such statements are based, unless so required by applicable law. The Group’s business is subject to the risk factors outlined in its registration documents filed with the French Autorité des Marchés Financiers. The risks and uncertainties set out are not exhaustive and the reader is advised to refer to the Group’s 2015 Registration Document available on its website (www.ipsen.com).
News Article | February 27, 2017
Significant investment in Primary Care Representatives for Key Products, Xifaxan® (rifaximin) and RELISTOR® (methylnaltrexone bromide) LAVAL, Quebec, Feb. 27, 2017 /PRNewswire/ -- Valeant Pharmaceuticals International, Inc.'s (NYSE: VRX and TSX: VRX) wholly owned subsidiary, Salix, a...
News Article | February 22, 2017
MILANO--(BUSINESS WIRE)--Un uomo si ritrova sperduto in un bosco, mentre cala la notte. Trova una torcia che emana una luce fioca e lo aiuta a muoversi tra gli alberi, in cerca di una via d’uscita dalla fitta oscurità che lo sta avvolgendo. Inizia così “In the Woods”, il cortometraggio voluto dall’azienda biofarmaceutica Dompé in occasione della Giornata mondiale delle malattie rare, presentato oggi nell’ambito della campagna social #fightforlight. È Gabriele Mainetti, regista di “Lo chiamavano Jeeg Robot”, a dare un volto a quanti soffrono di malattie rare degli occhi. Per queste persone, la strada per “ritrovare la luce” è complicata: momenti di sconforto, stanchezza, difficoltà, vie impervie che possono rivelarsi sbagliate. Proprio come accade al protagonista, che si destreggia tra lo sgomento, la fatica e lo smarrimento di un bosco a lui sconosciuto, alla ricerca della luce. I raggi di una prospettiva di speranza sono metaforicamente rappresentati da un risveglio che, l’indomani, inonda di luce il volto del protagonista. “Any advance in research is a ray of hope” (Ogni progresso in ricerca è un raggio di speranza): questo il messaggio che chiude il video, a ricordare che la ricerca può rappresentare un’arma capace di sconfiggere l’oscurità della malattia. “Per quanto la natura sia tutt’altro che democratica, l’obiettivo di garantire a tutti la stessa qualità di vita è profondamente umano”, racconta Gabriele Mainetti parlando della sua interpretazione. “Credo nella ricerca e nella sua lotta per aiutare chi si è perso nel buio”. “Con questa campagna vogliamo continuare a dare forza a un percorso che ha come obiettivo quello di contribuire a far luce sul mondo dei pazienti affetti da malattie rare e sui loro bisogni di salute”, spiega Eugenio Aringhieri, CEO del Gruppo Dompé. “La ricerca di nuove prospettive terapeutiche rappresenta una parte importante di questo mondo. Una sfida lunga e complessa che per certi versi evoca l’esperienza vissuta dal protagonista del video. Sfida che sono convinto debba essere combattuta in squadra, riunendo le diverse prospettive intorno a un unico obiettivo: il Paziente”. “Le malattie rare degli occhi rappresentano un ambito in cui sono ancora molte le risposte che i pazienti attendono”, afferma Paolo Rama, Primario dell'Unità Operativa di Oculistica – Cornea e Superficie Oculare dell'IRCCS Ospedale San Raffaele. “La ricerca italiana deve molto agli studi condotti dal Premio Nobel Rita Levi Montalcini su NGF, una proteina naturalmente prodotta dal corpo umano, responsabile dello sviluppo, del mantenimento e della sopravvivenza delle cellule nervose, per cui siamo in attesa dei risultati dei trial clinici che abbiamo condotto e che potrebbe rappresentare una vera innovazione in determinati ambiti dell’oftalmologia.” “Lo sviluppo della ricerca e l'accesso all'innovazione sono essenziali per chi ha una patologia rara e rappresentano in modo concreto la speranza per combattere e vincere la malattia. Come movimento di partecipazione civica a tutela dei diritti dei cittadini e dei soggetti in condizioni di debolezza, Cittadinanzattiva incoraggia progetti di sensibilizzazione come questo che, essendo rivolti all’opinione pubblica, possono contribuire a una maggiore consapevolezza sulle malattie rare che devono rappresentare sempre più un tema chiave per la sanità pubblica”, spiega Francesca Moccia, Vice Segretario Generale Cittadinanzattiva, intervenuta all’anteprima del video. Il video, che si accompagna all’hashtag #fightforlight per la condivisione in rete e sui social, è visualizzabile sul canale Youtube Dompé, insieme ad altri contenuti di backstage legati alla campagna. Per vedere e condividere “In the Woods”: https://youtu.be/YIOA9ajZ0Gw Dompé è una delle principali aziende biofarmaceutiche in Italia, focalizzata sullo sviluppo di soluzioni terapeutiche innovative per patologie ad alto impatto sociale, spesso orfane di cura. Con sede in Italia, Dompé ha il proprio quartier generale a Milano e concentra il proprio impegno in Ricerca in aree con bisogni terapeutici ancora insoddisfatti quali il diabete, il trapianto d’organo, l’oftalmologia, e l’oncologia. Il polo industriale dell’Aquila (Abruzzo) ospita un impianto biotecnologico d’eccellenza nel mondo e sviluppa farmaci per la Primary Care destinati ai mercati di circa 40 paesi nel mondo. Dompé è inoltre presente con propri uffici in Albania, Francia, Germania, Gran Bretagna, Spagna e negli Stati Uniti (New York).